Maze Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Phase II HORIZON data show MZE829 achieved a 36% mean reduction in proteinuria in broad AMKD, with 61.8% reduction in FSGS and 48.6% in non-diabetics. The drug was well-tolerated, and early diabetic data are promising. Plans are underway for a pivotal program.
-
The company is advancing two key programs: MZE-829 for APOL1-mediated kidney disease, aiming for first-in-class proof of concept with a fully funded phase 2b/3 study, and MZE-782 for PKU and CKD, showing best-in-class early data and planning phase 2 trials. Multiple clinical catalysts are expected this year, supported by strong financials and growing diagnostic infrastructure.
-
Key clinical programs are advancing, with MZE829 data expected soon and MZE782 phase 2 studies for PKU and CKD planned this year. The company’s dual-mechanism approach aims to improve outcomes in kidney and metabolic diseases, with a focus on regulatory pathways and patient impact.
-
Precision medicines for kidney and metabolic diseases are advancing, with MZE829 phase II data for APOL1 kidney disease expected by end of Q1 2026 and MZE782 phase II for PKU and CKD planned for 2026. Strong capital position supports all key milestones into 2028.
Fiscal Year 2025
-
Major milestones included going public, launching the MZE829 APOL1 kidney disease study, and advancing MZE782. The Horizon trial targets a broad AMKD population, aiming for a 30% proteinuria reduction, with pivotal data expected by Q1 2026. Strategic plans include phase 2b/3 studies and leveraging regulatory advances.
-
Focused on precision medicine for kidney and metabolic diseases, the company is advancing two lead small molecule programs—MZE829 for APOL1-mediated kidney disease and MZE782 for PKU and CKD—toward key phase II milestones in 2026, supported by strong clinical data and recent financing.
-
Recent conference presentations reinforced the genetic and mechanistic understanding of APOL1-mediated kidney disease, with a dual-mechanism inhibitor showing strong preclinical results and a pivotal clinical readout expected in Q1 2026. The pipeline also includes a promising SLC6A19 inhibitor for PKU and CKD.
-
The company is advancing precision medicines for kidney and metabolic diseases, with pivotal data for its APOL1-mediated kidney disease program expected in Q1 2026. Its pipeline includes promising candidates for both PKU and CKD, supported by strong preclinical and early clinical results.
-
Phase I results for MZE-782 in healthy volunteers showed excellent safety, linear PK, and robust, dose-dependent increases in urinary phenylalanine and glutamine excretion, confirming target engagement. An initial, reversible eGFR dip supports kidney benefit, enabling Phase II trials in PKU and CKD in 2026.